Scholarlink

Background <p>Breast cancer (BC) poses a serious threat to women’s health, and its diagnosis and treatment remain extremely challenging in clinical practice. This study aims to clarify the mechanism by which <i>lncRNA TAT-AS1</i> affects BC and evaluate its clinical value.</p> Methods <p><i>LncRNA TAT-AS1</i>, miR-3187-5p, and <i>RUNX1</i> mRNA levels were determined using RT-qPCR. Cell proliferation, apoptosis, migration, and invasion of cells were determined using CCK-8, flow cytometry, and Transwell assay. The targeted relationships between genes were verified through dual luciferase reporter assays, RNA pull-down assays, and RIP assays.</p> Results <p>In BC patients, <i>lncRNA TAT-AS1</i> and <i>RUNX1</i> were upregulated in plasma, while miR-3187-5p was downregulated. miR-3187-5p was a downstream target of <i>lncRNA TAT-AS1</i> and has a targeted binding relationship with <i>RUNX1</i>. Through the miR-3187-5p/<i>RUNX1</i> axis, <i>lncRNA TAT-AS1</i> promoted BC cell proliferation, apoptosis, migration, and invasion.</p> Conclusion <p>The lncRNA TAT-AS1 may have the ability to distinguish BC, and the discovery of the lncRNA TAT-AS1/miR-3187-5p/<i>RUNX1</i> regulatory axis provides a new strategy for targeted therapy.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

LncRNA TAT-AS1 promotes the progression of breast cancer through the hsa-miR-3187-5p/RUNX1 axis and its clinical value

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年4月25日

查看全文
  • Yu Liu,
  • Deyu Fu,
  • Qing Lu,
  • Kai Yin,
  • Xiaohong Xue

摘要

Background

Breast cancer (BC) poses a serious threat to women’s health, and its diagnosis and treatment remain extremely challenging in clinical practice. This study aims to clarify the mechanism by which lncRNA TAT-AS1 affects BC and evaluate its clinical value.

Methods

LncRNA TAT-AS1, miR-3187-5p, and RUNX1 mRNA levels were determined using RT-qPCR. Cell proliferation, apoptosis, migration, and invasion of cells were determined using CCK-8, flow cytometry, and Transwell assay. The targeted relationships between genes were verified through dual luciferase reporter assays, RNA pull-down assays, and RIP assays.

Results

In BC patients, lncRNA TAT-AS1 and RUNX1 were upregulated in plasma, while miR-3187-5p was downregulated. miR-3187-5p was a downstream target of lncRNA TAT-AS1 and has a targeted binding relationship with RUNX1. Through the miR-3187-5p/RUNX1 axis, lncRNA TAT-AS1 promoted BC cell proliferation, apoptosis, migration, and invasion.

Conclusion

The lncRNA TAT-AS1 may have the ability to distinguish BC, and the discovery of the lncRNA TAT-AS1/miR-3187-5p/RUNX1 regulatory axis provides a new strategy for targeted therapy.